EP
DSGN icon

Eversept Partners’s Design Therapeutics DSGN Stock Holding History

Eversept Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
+190,000
New +$2.37M 0.14% 84

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Eversept Partners's DSGN Position: Q2 2026 in Review

Eversept Partners opened a new position in Design Therapeutics (DSGN) in Q2 2026: 190,000 shares worth $2.75M. The stake represents 0.14% of the portfolio and ranks #84 among its holdings.

137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Eversept Partners held 190,000 shares of Design Therapeutics worth $2.75M as of Q2 2026.
  • Design Therapeutics was a new Eversept Partners position in Q2 2026.
  • Design Therapeutics made up 0.14% of Eversept Partners's portfolio in Q2 2026, its #84 holding.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.